FDA-Cleared AI Neuropsychiatry Platform, Million-Dose Ketamine Manufacturing and Presidential Psychedelic Initiative Drive Growing Momentum for NRXP

MIAMI - Rezul -- NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) $NRXP is rapidly emerging as one of the most closely watched companies in the mental health and neuropsychiatry sector as it advances a diversified platform spanning ketamine therapies, AI-powered Transcranial Magnetic Stimulation (TMS), neuroplastic treatments, and FDA-designated breakthrough drug candidates focused on suicidality, treatment-resistant bipolar depression, PTSD, and chronic pain.

The company's strategy combines pharmaceutical development with direct clinical delivery through its wholly-owned subsidiary HOPE Therapeutics, creating what management believes could become a vertically integrated leader in advanced psychiatric care and neuroplastic medicine.

NRXP recently announced several major developments that have significantly increased investor attention surrounding the company's 2026 outlook.

HOPE Therapeutics Deploys FDA-Cleared AI-Guided TMS Navigation System

On May 27th, NRXP announced that HOPE Therapeutics became the first commercial deployment site for Zeta Surgical's FDA-cleared Zeta TMS Navigation System at its West Palm Beach, Florida clinic.

The Zeta platform utilizes AI-powered sub-millimetric image guidance to precisely deliver Transcranial Magnetic Stimulation treatments for patients suffering from Major Depressive Disorder and other neurological conditions.

The deployment represents a significant advancement for NRXP's growing neuroplastic therapy ecosystem, which now includes:

• Ketamine therapy
• Spravato® administration
• Transcranial Magnetic Stimulation (TMS)
• Hyperbaric Oxygen Therapy
• Neuroplastic treatment protocols

Management believes this integrated treatment model may position HOPE Therapeutics as a leading interventional psychiatry platform targeting severe depression, suicidality, PTSD, and military-related trauma disorders.

Published clinical results referenced by the company have demonstrated clinical response rates as high as 87% when combining non-invasive TMS with neuroplastic medications.

FDA Provides Pathway Toward Approval of NRX-100 Ketamine

One of the most important recent developments for NRXP was the completion of a Type C Meeting with the FDA Division of Psychiatry Products and CDER leadership.

According to the company, the FDA demonstrated openness toward utilizing existing clinical trial data combined with Real World Evidence to support approval of NRX-100 without requiring additional large-scale trials.

More on Rezul News

• Four Seasons Cleaners Debuts Santa Barbara County's First 24/7 Dry Cleaning Kiosk New self-service
• WhereTu Launches to Help Americans Build Successful Lives Abroad
• Appliance EMT Expands Built-In and Walk-In Refrigerator Service in Metro Atlanta
• LawProactive Launches SB 37-Compliant Attorney Marketing Software With Exclusive City Territories Across California
• 303 Crown Maids Launches Enhanced Move-In / Move-Out Cleaning Service Page

NRX-100 is an intravenous preservative-free ketamine formulation being developed for the treatment of suicidal depression.

NRXP plans to submit approximately 70,000 patient data points involving real world ketamine use in suicidal depression as part of its regulatory strategy.

The ketamine market opportunity continues to grow globally, with the current worldwide generic ketamine market estimated at approximately $750 million annually.

The company also expects an anticipated FDA decision on its preservative-free ketamine ANDA during Q3 2026.

Importantly, the FDA has reportedly already provided favorable preliminary determinations regarding:

• Bioequivalence
• Labeling
• Drug substance
• Drug product
• Safety

If approved, NRXP's preservative-free ketamine could potentially become the first U.S.-manufactured preservative-free ketamine presentation commercially available in the market.

Commercial Manufacturing Underway Ahead of Potential Launch

NRXP recently initiated its first commercial manufacturing order for preservative-free ketamine in anticipation of potential regulatory approval.

The company stated that manufacturing is currently capable of producing approximately 1 million doses per month and can scale rapidly as demand increases.

The product is manufactured utilizing an advanced blow-fill-seal production process that reportedly delivers significantly higher throughput compared to traditional sterile vial manufacturing systems.

Importantly, NRXP's ketamine formulation does not contain Benzethonium Chloride, a preservative management notes is no longer permitted in new drugs due to toxicity concerns.

The company believes this differentiation may provide meaningful commercial and safety advantages compared to legacy ketamine formulations currently available.

NRX-101 Continues Advancing as FDA Breakthrough Therapy

NRXP continues development of NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain.

The treatment combines D-cycloserine with lurasidone and is being studied in combination with robotic-enabled TMS.

The FDA recently accepted an Investigational New Drug application for NRX-101 as an adjunct to robotic-enabled TMS.

Management has indicated the study is expected to receive non-dilutive federal support and will include military and civilian treatment centers.

The company is also developing a patentable sustained-release D-cycloserine formulation designed to significantly enhance TMS efficacy.

Prior trial data cited by the company demonstrated:

• A doubling of clinical response rates
• An eight-fold increase in remission rates versus standard TMS

These results could represent a potentially major advancement in the treatment of severe depression and suicidality.

More on Rezul News

• Cogs and Marvel expands EMEA leadership team for next phase of growth
• Beat the Philly Heat: Mid-July AC Boost
• Ostara Systems announce new CAFM software client: Papas Group
• Dave Freer's "Storm-Dragon" Wins First-Ever Prometheus Special Award For Young Adult Fiction
• T. Jones Group Celebrates Two Wins and Multiple Project Nominations at the 2026 HAVAN Awards

Presidential Executive Order Could Accelerate Psychedelic Drug Development

On April 18th, 2026, President Donald Trump signed an Executive Order titled "Accelerating Medical Treatments for Serious Mental Illness."

The order specifically supports the acceleration of innovative research models and approvals for psychedelic-related medications targeting depression, PTSD, suicidality, and severe mental illness.

NRXP welcomed the announcement, particularly because the company has applied for a Commissioner's National Priority Voucher (CNPV) in support of its upcoming NRX-100 New Drug Application.

The executive order also directs increased collaboration between the FDA, Department of Veterans Affairs, HHS, and private sector organizations to expand clinical trials, data sharing, and Real World Evidence generation for psychedelic-related therapies.

Management believes these initiatives may substantially support NRXP's regulatory strategy utilizing existing federal trial data and real-world ketamine treatment outcomes.

Strongly Improved Financial Results and Strategic Expansion

NRXP reported significantly improved first quarter 2026 financial results compared to the same period in 2025.

The company reported a net loss of approximately $1.4 million compared to a net loss of approximately $5.5 million during Q1 2025.

As of March 31st, 2026, NRXP reported approximately $6.7 million in cash and cash equivalents.

Management stated that current cash resources, anticipated clinic revenue growth, cost reduction initiatives, and additional capital availability are expected to support operations through 2026.

Meanwhile, HOPE Therapeutics has already begun generating revenue from five interventional psychiatry clinics focused on severe depression and PTSD treatment.

The company expects significant expansion of its clinic footprint throughout 2026.

Analyst Coverage and Expanding Investor Interest

D. Boral recently issued a Buy rating on NRXP with a $34 price target, citing the company's diversified mental health platform, ketamine commercialization potential, and breakthrough psychiatry pipeline.

With FDA momentum building, commercialization initiatives accelerating, and growing national attention on advanced mental health treatments, investors are increasingly watching NRXP as a potentially significant emerging player within the rapidly evolving neuropsychiatric therapeutics sector.

For more information on $NRXP visit: https://www.nrxpharma.com/ and https://compasslivemedia.com/case-study/nrx-pharmaceuticals/

Company Contact
NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP)
Matthew Duffy – Chief Business Officer
Phone: (484) 254-6134
Email: mduffy@nrxpharma.com

DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website